Placeholder Banner

BIO Submits Comments on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses Proposed Rule

March 20, 2019

BIO submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed rule, Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses Proposed Rule.

BIO is extremely concerned the Agency continues to erode the value of the Medicare benefit for seniors, placing patient access at risk. This proposed rule prioritizes cost containment policies over patient healthcare needs. BIO respectfully requests the Agency and Administration instead focus on holistic solutions to balance the financial sustainability of the Medicare program, while addressing patient out-of-pocket cost and access to appropriate treatment. In the comments, BIO provides specific recommendations for how CMS can improve the proposed rule and ensure greater access for patients while directly reducing OOP costs.

Download Full Comments Below
FINAL BIO Comment Letter MA And Part D Proposed Rule 1 25 19
See the full comment letter here:
Discover More
July 31, 2020 Re: Docket No. FDA–2020-N-0837: Raare Disease Clinical Trial Network; Request for Information. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the…
July 30, 2020 Re: Docket No. FDA–2019-D-5799: FDA’s Public Meeting, Modernizing the Food and Drug Administration’s Data Strategy. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or…
The following letter provides BIO’s feedback on a number of regulatory proposals by the Centers for Medicare & Medicaid Services that would ease barriers to use of value-based purchasing arrangements within Medicaid and commercial plans, broaden…